Mission statement · Company scope
“Our mission is to build a leading, fully integrated global rare disease company using our patient-centric approach to identify and develop life-transforming medicines for the treatment of severe rare diseases.”
In use2023 – now1 sighting
First seenApr 2023Added
Last seenApr 2023Latest observation
Date created—Not published by the organization
Record
- Kind
- Mission
- Scope
- Company
- Style
- Market leadership (primary) · Product offering · Impact
- Leads with
- Rank
- Best for
- Climate & health
- Formula
- The [rank] [category] for [who]
- Tone
- Plain
- Length
- 30 words · reading grade 19
- Review status
- unreviewed · classifier rules-v0
- Quality score
- 0.75
- Record
- st_68794763c5fbd042
- Classification confidence
- 0.79
Sources1 sighting
SEC
SEC EDGAR filingsObserved 2023-04-19 · sec_sentence · 20-F · accession 0000950170-23-013373
View filing ↗0 to compareCompare